320.37 -2.67 (-0.83%)
Pre-Market: 8:17AM EST
|Bid||326.40 x 200|
|Ask||329.00 x 100|
|Day's Range||322.10 - 332.41|
|52 Week Range||313.53 - 543.55|
|PE Ratio (TTM)||31.24|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||426.32|
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.
Major indexes are up after moderate early losses. Few stocks are breaking out, though. Bitcoin Investment Trust is still well off its peak.
Jim Cramer looks at the investment strategies you need to use throughout your life, especially in a volatile market.
Regeneron should benefit after Novartis and Roche presented data for competitors to blockbuster eye drug Eylea.
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average ...
TARRYTOWN, N.Y., Feb. 12, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced the appointment of Marion McCourt as the Senior Vice President and Head of Commercial. Ms. McCourt joined Regeneron today to lead all aspects of product commercialization for Regeneron's currently approved medicines and development-stage pipeline. "Marion is an accomplished biopharmaceutical executive who brings a track record of success in commercializing products and leading commercial teams," said Leonard S. Schleifer, MD, PhD, President and Chief Executive Officer of Regeneron.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) has been in steady decline since July, and one analyst, though conceding the selloff from $500 was justified, said the Street’s taken it too far. The Rating ...
Stock Monitor: Regeneron Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If you ...
Regeneron reported adjusted income of $5.23 per share on $1.58 billion in sales for the fourth quarter.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) delivered an ROE of 24.25% over the past 12 months, which is an impressive feat relative to its industry average of 16.12% during the same period.Read More...
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Fears of the demise of blockbuster eye drug Eylea were "greatly exaggerated," Regeneron Pharmaceuticals Inc's chief executive said on Thursday, after the treatment and new eczema drug Dupixent powered the company's fourth-quarter results. Investors have long fretted over Eylea's grip on the market, as the drug that has driven Regeneron's growth since 2011 faces a potential threat of rival treatments from Novartis AG and Roche Holding AG.
Regeneron Pharmaceuticals Inc. shares rose 4.2% in premarket trade Thursday after the company reported fourth-quarter profit and revenue beats. Earnings for the latest quarter declined to $174 million, ...
The Tarrytown, New York-based company said it had net income of $1.50 per share. Earnings, adjusted for pretax expenses and stock option expense, were $5.23 per share. The results surpassed Wall Street ...
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 8:30 ...
Regeneron Pharmaceuticals Inc's quarterly profit fell about 31 percent on Thursday, due to a charge of $381 million related to changes in U.S. tax laws. Net income fell to $173.5 million, or $1.50 per ...